Revamping the corneal permeability and antiglaucoma therapeutic potential of brinzolamide using transniosomes: optimization, in vitro and preclinical evaluation

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Mohsen AM, Salama A, Kassem AA. Development of acetazolamide loaded bilosomes for improved ocular delivery: preparation, characterization and in vivo evaluation. J. Drug Deliv. Sci. Technol. 59(2), 1–16 (2020).
  Google Scholar
• 2. Nair VS, Srivastava V, Bhavana V et al. Exploring penetration ability of carbonic anhydrase inhibitor-loaded ultradeformable bilosome for effective ocular application. AAPS PharmSciTech 24(6), 1–15 (2023). •• Exhaustive summary about bilosomes and their characterizations.
  Google Scholar
• 3. Kassem AA, Salama A, Mohsen AM. Formulation and optimization of cationic nanoemulsions for enhanced ocular delivery of dorzolamide hydrochloride using Box–Behnken design: in vitro and in vivo assessments. J. Drug Deliv. Sci. Technol. 68(1), 134–149 (2022).
  Google Scholar
• 4. Abuallut I, Shubayli S, Qumayri G et al. Awareness and knowledge of glaucoma and its associated risk factors among adult population in the Jazan region, Saudi Arabia. Cureus 15(11), 22–34 (2023). • Exhaustive knowledge about glaucoma and its epidemiology.
  Google Scholar
• 5. Zhang X, Wang F, Su Y. TRPV: an emerging target in glaucoma and optic nerve damage. Exp. Eye Res. 239(2), 1084–1097 (2024).
  Google Scholar
• 6. Salowe RJ, Chen Y, Zenebe-Gete S et al. Risk factors for structural and functional progression of primary open-angle glaucoma in an African ancestry cohort. BMJ Open Ophthalmol. 8(2), 1129 (2023).
  Google Scholar
• 7. Lu P, Liang Z, Zhang Z et al. Novel nanomicelle butenafine formulation for ocular drug delivery against fungal keratitis: in vitro and in vivo study. Eur. J. Pharm. Sci. 192(3), 1029–1037 (2024).
  Google Scholar
• 8. Suri R, Beg S, Kohli K. Target strategies for drug delivery bypassing ocular barriers. J. Drug Deliv. Sci. Technol. 55(19), 1–62 (2020). • Comprehensive information about ocular barriers.
  Google Scholar
• 9. Srivastava V, Chary PS, Rajana N et al. Complex ophthalmic formulation technologies: advancement and future perspectives. J. Drug Deliv. Sci. Technol. 82(1), 1–22 (2023).
  Google Scholar
• 10. Bhosale VA, Srivastava V, Valamla B, Yadav R, Singh SB, Mehra NK. Preparation and evaluation of modified chitosan nanoparticles using anionic sodium alginate polymer for treatment of ocular disease. Pharmaceutics 14(12), 1–20 (2022).
  Google Scholar
• 11. Zeng S, Chen Y, Zhou F et al. Recent advances and prospects for lipid-based nanoparticles as drug carriers in the treatment of human retinal diseases. Adv. Drug Deliv. Rev. 199(2), 1149–1167 (2023).
  Google Scholar
• 12. Laddha UD, Kshirsagar SJ. Formulation of nanoparticles loaded in situ gel for treatment of dry eye disease: in vitro, ex vivo and in vivo evidences. J. Drug Deliv. Sci. Technol. 61(3), 1021–1029 (2021).
  Google Scholar
• 13. Nagpal N, Singh S, Mir PA et al. Ocuserts: a novel ocular-drug delivery method: an update. World J. Biol. Pharm. Heal. Sci. 13(1), 470–477 (2023).
  Google Scholar
• 14. Wang X, Luan F, Yue H et al. Recent advances of smart materials for ocular drug delivery. Adv. Drug Deliv. Rev. 200(2), 1150–1175 (2023).
  Google Scholar
• 15. Teabagy S, Wood E, Bilsbury E, Doherty S, Janardhana P, Lee DJ. Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis. Adv. Drug Deliv. Rev. 198(2), 1–11 (2023).
  Google Scholar
• 16. Mostafa M, Al Fatease A, Alany RG, Abdelkader H. Recent advances of ocular drug delivery systems: prominence of ocular implants for chronic eye diseases. Pharmaceutics 15(6), 1746–1796 (2023).
  Medline CASGoogle Scholar
• 17. Wei D, Pu N, Li SY, Wang YG, Tao Y. Application of iontophoresis in ophthalmic practice: an innovative strategy to deliver drugs into the eye. Drug Deliv. 30(1), 1–13 (2023).
  Google Scholar
• 18. Vasdev N, Chaudhari N, Polaka S et al. Current progress in preservative-free topical ophthalmic formulations. J. Drug Deliv. Sci. Technol. 79(4), 1–20 (2023).
  Google Scholar
• 19. Kaviarasi B, Rajana N, Pooja YS, Rajalakshmi AN, Singh SB, Mehra NK. Investigating the effectiveness of difluprednate-loaded core-shell lipid-polymeric hybrid nanoparticles for ocular delivery. Int. J. Pharm. 640(2), 12–29 (2023).
  Google Scholar
• 20. Alyami H, Abdelaziz K, Dahmash EZ, Iyire A. Nonionic surfactant vesicles (niosomes) for ocular drug delivery: development, evaluation and toxicological profiling. J. Drug Deliv. Sci. Technol. 60(August), 1–16 (2020).
  Google Scholar
• 21. Srivastava V, Singh V, Kumar Khatri D, Kumar Mehra N. Recent trends and updates on ultradeformable and elastic vesicles in ocular drug delivery. Drug Discov. Today 28(8), 103647 (2023). •• Exhaustive summary about vesicular systems, significance of deformability in ocular drug delivery.
  Medline CASGoogle Scholar
• 22. Gupta DK, Aqil M, Ahad A et al. Tailoring of berberine loaded transniosomes for the management of skin cancer in mice. J. Drug Deliv. Sci. Technol. 60(1), 20–51 (2020).
  Google Scholar
• 23. Bagul US, Nazirkar MV, Mane AK, Khot SV, Tagalpallewar AA, Kokare CR. Fabrication of architectonic nanosponges for intraocular delivery of brinzolamide: an insight into QbD driven optimization, in vitro characterization, and pharmacodynamics. Int. J. Pharm. 650(2), 1237–1246 (2024).
  Google Scholar
• 24. Ma Y, Zhang Z, Yu Y et al. Nanomaterials in the diagnosis and treatment of ophthalmic diseases. Nano Today 54, 102117 (2024).
  CASGoogle Scholar
• 25. Dubey V, Mohan P, Dangi JS, Kesavan K. Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: formulation, characterization and pharmacodynamic study. Int. J. Biol. Macromol. 19(3), 1–40 (2019).
  CASGoogle Scholar
• 26. Joshi A, Kaur J, Kulkarni R, Chaudhari R. In-vitro and ex-vivo evaluation of raloxifene hydrochloride delivery using nano-transfersome based formulations. J. Drug Deliv. Sci. Technol. 45(2), 151–158 (2018).
  CASGoogle Scholar
• 27. Shukr MH. Novel in situ gelling ocular inserts for voriconazole-loaded niosomes: design, in vitro characterisation and in vivo evaluation of the ocular irritation and drug pharmacokinetics. J. Microencapsul. 33(1), 71–79 (2016).
  Medline CASGoogle Scholar
• 28. Khatoon K, Rizwanullah M, Amin S, Mir SR, Akhter S. Cilnidipine loaded transfersomes for transdermal application: formulation optimization, in-vitro and in-vivo study. J. Drug Deliv. Sci. Technol. 54(1), 1013–1034 (2019).
  Google Scholar
• 29. Nikita, Aqil M, Sultana Y. A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and stability study. Eur. J. Pharm. Sci. 159, 105735 (2021).
  Medline CASGoogle Scholar
• 30. Franca JR, Fuscaldi LL, Ribeiro TG et al. Use of chitosan as pharmaceutical excipient in ocular drug delivery systems: sterilization and pharmacokinetics. J. Biomed. Mater. Res. Part B Appl. Biomater. 108(5), 2227–2237 (2020).
  Medline CASGoogle Scholar
• 31. ICCVAM (Interagency Coordinating Committee on the Validation of Alternative Methods) Recommended Test Method Protocol. Hen's egg test – chorioallantoic membrane (HET-CAM) test method. (10), 3–30 (2010).
  Google Scholar
• 32. Ali A, Aqil M, Sarim Imam S et al. Formulation and evaluation of embelin loaded nanoliposomes: optimization, in vitro and ex vivo evaluation. J. Drug Deliv. Sci. Technol. 72(2), 1–8 (2022).
  Google Scholar
• 33. Chen Y, Lu Y, Zhong Y, Wang Q, Wu W, Gao S. Ocular delivery of cyclosporine A based on glyceryl monooleate/poloxamer 407 liquid crystalline nanoparticles: preparation, characterization, in vitro corneal penetration and ocular irritation. J. Drug Target. 20(10), 856–863 (2012).
  Medline CASGoogle Scholar
• 34. Patel GC, Phan TN, Maddineni P et al. Dexamethasone-induced ocular hypertension in mice: effects of myocilin and route of administration. Am. J. Pathol. 187(4), 713–723 (2017).
  Medline CASGoogle Scholar
• 35. ElMeshad AN, Mohsen AM. Enhanced corneal permeation and antimycotic activity of itraconazole against Candida albicans via a novel nanosystem vesicle. Drug Deliv. 23(7), 2115–2123 (2016).
  Medline CASGoogle Scholar
• 36. Sakr MG, El-Zahaby SA, Al-Mahallawi AM, Ghorab DM. Fabrication of betaxolol hydrochloride-loaded highly permeable ocular bilosomes (HPOBs) to combat glaucoma: in vitro, ex vivo and in vivo characterizations. J. Drug Deliv. Sci. Technol. 82(4), 1043–1063 (2023).
  Google Scholar
• 37. Wang JJ, Zhao YP, Yu AYY et al. Effect of travoprost, latanoprost and bimatoprost PGF2α treatments on the biomechanical properties of in-vivo rabbit cornea. Exp. Eye Res. 215(1), 1–15 (2022).
  Google Scholar
• 38. Kaviarasi B, Rajana N, Pooja YS, Rajalakshmi AN, Singh SB, Mehra NK. Investigating the effectiveness of difluprednate-loaded core-shell lipid-polymeric hybrid nanoparticles for ocular delivery. Int. J. Pharm. 640(1), 1–12 (2023).
  Google Scholar
• 39. Zhou Y, Fang A, Wang F et al. Core-shell lipid-polymer nanoparticles as a promising ocular drug delivery system to treat glaucoma. Chinese Chem. Lett. 31(2), 494–500 (2020).
  CASGoogle Scholar
• 40. Sittewelle M, Royle SJ. Passive diffusion accounts for the majority of intracellular nanovesicle transport. Life Sci. Alliance 7(1), 1–14 (2024).
  Google Scholar
• 41. Zafar A, Alruwaili NK, Imam SS et al. Development and optimization of nanolipid-based formulation of diclofenac sodium: in vitro characterization and preclinical evaluation. Pharmaceutics 14(3), 32–40 (2022).
  Google Scholar